| __timestamp | Arrowhead Pharmaceuticals, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 24419536 | 1213000 |
| Thursday, January 1, 2015 | 34718089 | 3425000 |
| Friday, January 1, 2016 | 40998209 | 6311000 |
| Sunday, January 1, 2017 | 32022880 | 9518000 |
| Monday, January 1, 2018 | 19110051 | 28080000 |
| Tuesday, January 1, 2019 | 26556257 | 36550000 |
| Wednesday, January 1, 2020 | 52275890 | 46125000 |
| Friday, January 1, 2021 | 80981000 | 68486000 |
| Saturday, January 1, 2022 | 124431000 | 92032000 |
| Sunday, January 1, 2023 | 90932000 | 117532000 |
| Monday, January 1, 2024 | 98761000 |
Data in motion
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Arrowhead Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Arrowhead's SG&A expenses grew by approximately 300%, peaking in 2022. In contrast, Rhythm Pharmaceuticals saw a staggering increase of nearly 9,600% over the same period, with a notable spike in 2023. This dramatic rise highlights Rhythm's aggressive expansion strategy, while Arrowhead's steadier growth suggests a more controlled approach. However, the absence of data for Rhythm in 2024 leaves room for speculation about their future trajectory. As these companies navigate the complexities of the pharmaceutical industry, their ability to manage SG&A costs will be pivotal in determining their long-term success.
Gilead Sciences, Inc. vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Genmab A/S vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Comparing SG&A Expenses: Alkermes plc vs Arrowhead Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Rhythm Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Arrowhead Pharmaceuticals, Inc. and Mesoblast Limited
Arrowhead Pharmaceuticals, Inc. and Geron Corporation: SG&A Spending Patterns Compared
Arrowhead Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Arrowhead Pharmaceuticals, Inc. and Evotec SE